Status:
COMPLETED
COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
Lead Sponsor:
Nikita Gupta
Conditions:
COVID-19
SARS-CoV 2
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses. It has been previously used in both intranasal preparations against Methicillin Resistant Sta...
Detailed Description
The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2), has been implicated in over 12 million cases and counting in the United States alone and has killed at ...
Eligibility Criteria
Inclusion
- healthcare worker OR
- patient with expected hospital stay of 7+ days OR
- patient admitted for major surgery OR
- community member
- COVID19 negative by nasal swab test
- asymptomatic for COVID19
- able to consent
Exclusion
- positive for COVID19 by nasal swab
- symptomatic for COVID19
- unable to consent
Key Trial Info
Start Date :
April 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 28 2022
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT04364802
Start Date
April 29 2020
End Date
January 28 2022
Last Update
December 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky
Lexington, Kentucky, United States, 40536